Dietmar Berger

Alessa Therapeutics

Cam Gallagher

Alessa Therapeutics has appointed Cam Gallagher as president and chief executive officer. Gallagher has over 30 years of experience in the biotechnology industry. He most recently served as president, co-founder and board member at Zentalis Pharmaceuticals, and was previously chief business officer at Immusoft Corporation and Retrosense Therapeutics.

Anaveon

Richard Sachse

Anaveon has appointed Richard Sachse as chief medical officer. Sachse, who has more than 25 years of experience in the biopharma industry as a physician and scientist, has most recently been serving as chief medical officer of SOTIO Biotech. He was previously chief scientific officer at Neovii and has held roles at Bayer, UCB and Boehringer Ingelheim.

Shinobi Therapeutics

Luis Borges

Shinobi Therapeutics has appointed Luis Borges as chief scientific officer. Borges joins the company with almost three decades of experience in scientific and executive leadership. He previously served as chief scientific officer at Century Therapeutics, Metagenomi and Cell Medica, and was also scientific director in Amgen's haematology and oncology division.

Shinobi Therapeutics

Steven Katz

Shinobi Therapeutics has appointed Steven Katz as chief medical officer. Katz has more than 15 years of experience in clinical oncology leadership, translational science and clinical development of immunotherapeutics. He most recently served as chief medical officer at TriSalus Life Sciences and previously held a variety of positions at Roger Williams Medical Center.

Richmond Pharmacology

Matej Goricar

Richmond Pharmacology has appointed Matej Goricar as associate medical director. Goricar has experience working in both the NHS and private sector. He first joined Richmond as research physician, before progressing to clinical research physician, senior research physician and then to his most recent position as lead research physician.

Richmond Pharmacology

Amir Majid

Richmond Pharmacology has appointed Amir Majid as associate medical director. With experience in anaesthesia and clinical pharmacology, Majid has held roles of increasing responsibility at Richmond, culminating in his most recent position as lead research physician. Prior to joining the company, he worked at Chelsea and Westminster Hospital NHS Foundation Trust.

Kling Biotherapeutics

Rob Roovers

Kling Biotherapeutics has appointed Rob Roovers as director of preclinical development. Roovers brings extensive industry to his latest role, having most recently served as head of preclinical development at LAVA Therapeutics. Prior to joining LAVA, Roovers worked at Merus, where he co-developed the company's bispecifics.

Kling Biotherapeutics

Alessandra Villa

Kling Biotherapeutics has appointed Alessandra Villa as director of platform development. Villa brings significant experience to the role and joins the company from Molecular Partners, where she served as director lead generation, group leader. Prior to this, Villa held multiple roles at Philochem, including her most recent position as head of antibody research, group leader.